{
    "pmcid": "9896449",
    "qa_pairs": {
        "What is the primary target of the shark-derived nanobodies developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What potential application is suggested for the multi-specific nanobodies designed in the study?": [
            "Therapeutic application with robust neutralization and effector functions",
            "Use as a diagnostic tool for detecting SARS-CoV-2 in clinical samples",
            "Development as a vaccine adjuvant to enhance immune responses",
            "Application in gene therapy to deliver antiviral genes to infected cells"
        ],
        "What unique characteristic of shark antibodies is highlighted in the study?": [
            "They lack light chains and have a variable domain (VNAR) that is the smallest known natural binding domain",
            "They have an exceptionally large constant region compared to other antibodies",
            "They possess a dual-variable domain structure similar to camelid antibodies",
            "They contain a unique heavy chain that binds directly to viral RNA"
        ],
        "What was the outcome of in vivo studies using K18-hACE2 transgenic mice?": [
            "ShAb01 provided greater protection against SARS-CoV-2 challenge than ShAb02",
            "ShAb02 provided greater protection against SARS-CoV-2 challenge than ShAb01",
            "Neither ShAb01 nor ShAb02 provided significant protection against SARS-CoV-2 challenge",
            "Both ShAb01 and ShAb02 provided equal protection against SARS-CoV-2 challenge"
        ],
        "Which two VNAR-Fc chimeras were identified for their potent neutralization of SARS-CoV-2 variants?": [
            "ShAb01 and ShAb02",
            "ShAb03 and ShAb04",
            "ShAb05 and ShAb06",
            "ShAb07 and ShAb08"
        ]
    }
}